Clin2
NCT07654517Possibly a fitNot yet recruiting

Testing pirfenidone for a rare throat condition

Idiopathic Subglottic StenosisSubglottic Stenosis (SGS)

Treatments studied

Part of Lungs & breathing clinical trials.

This trial tests if the drug pirfenidone is safe and tolerable for people with idiopathic subglottic stenosis (a narrowing of the windpipe below the vocal cords). It may help reduce the need for repeat throat dilation procedures.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
40 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have been diagnosed with idiopathic subglottic stenosis (iSGS).
  • You have had at least 2 dilation procedures in the past year, or you receive steroid injections every 3 months for your condition.
  • You are not currently smoking and are willing to avoid smoking during the treatment.
  • You have adequate liver and kidney function (checked by a blood test).
  • If you could become pregnant, you agree to use effective birth control and have a negative pregnancy test before starting.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07228104Recruiting· Phase 3
Steroid treatment after surgery for idiopathic subglottic stenosis

This study tests whether giving steroids after a procedure to open your windpipe can reduce the chance that the narrowing comes back. If you have this condition, the trial is looking for people who are healthy enough to take part.

San Diego, California
NCT07679893Recruiting· Phase 2
Inhaled nintedanib for idiopathic pulmonary fibrosis

This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.

Windsor, Ontario
NCT07121413Recruiting· Phase 2
Testing SV001 for Idiopathic Pulmonary Fibrosis

This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.

Chengdu
NCT06482190Recruiting· Phase 1
Safety study of an inhaled drug in healthy adults

This trial tests the safety of a new inhaled medicine. You must be a healthy nonsmoker, have normal lung function, and agree to avoid certain medications and foods.

Geelong, Victoria
NCT05288179Recruiting· Phase 3
Pirfenidone capsules for silicosis or coal dust lung disease

This Phase 3 trial tests whether pirfenidone slows or improves lung damage in people with silicosis or coal worker’s pneumoconiosis. It looks at both effectiveness and side effects, and uses lung function tests and lung scans to track changes over time.

Beijing
NCT06267183Recruiting· Early Phase 1
Safety study of a new drug in healthy volunteers

This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.

Shanghai

Hear when a new Subglottic Stenosis (SGS) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.